Autosomal Recessive Cerebellar Ataxia Due to a DNA Repair Defect

Neurology

Prevalence

5.0 / 100K

0 drugs in development·0 companies·1 clinical trial

Frequently asked questions

How many clinical trials target Autosomal Recessive Cerebellar Ataxia Due to a DNA Repair Defect?

There are 1 clinical trial targeting Autosomal Recessive Cerebellar Ataxia Due to a DNA Repair Defect tracked by BioSniper.

What is the prevalence of Autosomal Recessive Cerebellar Ataxia Due to a DNA Repair Defect?

The estimated prevalence of Autosomal Recessive Cerebellar Ataxia Due to a DNA Repair Defect is approximately 5.0 per 100,000 population.

Deep-dive into Autosomal Recessive Cerebellar Ataxia Due to a DNA Repair Defect

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    Autosomal Recessive Cerebellar Ataxia Due to a DNA Repair Defect — Drugs in Development & Clinical Trials | BioSniper